Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $433 to $400.
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $433 to $400.